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Clostridium perfringens type C produces beta toxin, which is a primary virulence
determinate that can cause necrotic enteritis in neonatal animals. Vaccines directed
against C. perfringens toxins have shown to be efficacious in preventing disease.
However, the production of a commercial vaccine requires not only an efficacious
antigen, but also testing methods for quantifying antigens and potency on final product.
This research was undertaken to fulfill a need for the reduction in small animal usage to
produce and deliver vaccines. The current testing methods are performed in vivo
according to the Code of Federal Regulations number 9 (9CFR) United States
Department of Agriculture (USDA) and European Pharmacopeia (EP) monograph
guidelines. With limited in vitro alternatives, the aim of this work was to develop an
enzyme-linked immunosorbent assay (ELISA) to be able to measure C. perfringens type
C beta toxoid, independent of laboratory animals. To accomplish this, investigational
polyclonal and monoclonal antibody candidates were screened for their specificity to beta
toxin and toxoid through western blot and ELISA. Additionally, through a neutralization
assay, the capability to neutralize beta toxin was demonstrated. Through this process,
one polyclonal antibody and one monoclonal antibody were selected and an in-process

ELISA for quantifying beta toxoid was developed. By using the ELISA to quantify beta
toxoid, the current practice of testing in animals could be reduced.
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CHAPTER I
INTRODUCTION
Clostridium perfringens, a Gram positive anaerobic rod shaped bacterium, is a
major cause of enteric disease in both humans and livestock. One such enteric disease is
necrotic enteritis, a severe disease found in animals that can have a significant negative
financial impact to agricultural markets (Keyburn et al., 2010; Smedley et al., 2004). In
addition to animal diseases, C. perfringens causes food poisoning and gas gangrene in
humans. There are five toxinotypes, A thru E, of C. perfringens that are classified based
on the type of toxins each produces. C. perfringens type C produces alpha and beta
toxin, with beta toxin being the primary virulence factor of necrotic enteritis in neonates.
C. perfringens can be found in many environments, such as soil, waste water,
food, feces and in both healthy human and animal intestines as normal flora. Vaccination
of animals can help prevent outbreaks of disease in livestock. These vaccines use
inactivated whole bacteria, recombinant proteins and/or purified toxoids. One obstacle to
producing more efficacious vaccines is complying with required potency testing as
mandated by the United States Department of Agriculture (USDA) and European
Pharmacopoeia (EP). Currently, the in vivo methods available for potency testing cause
pain, suffering and death in laboratory animals. Development of an in vitro assay to
measure vaccine potency would minimize animal use and support commercialization of
effective vaccines. This is long overdue as C. perfringens species have been known since
the turn of the century and scientists have been searching for effective vaccines since the
early 1900s.

2
1.1 HISTORY OF CLOSTRIDIUM PERFRINGENS
In 1892, William Welch and George Nuttall discovered Bacillus aerogenes
capsulatus during the postmortem examination of a 38 year old man at John Hopkins
University. The use of cultivation media and dyes (i.e., methylene-blue, gentian-violet
and fuchsine) permitted Welch and Nuttall to observe the bacterium’s morphological
features by fixing and staining the bacteria for microscopy. They observed that Bacillus
aerogenes capsulatus was a rod shaped bacilli that was at times encapsulated (Welch and
Nuttall, 1892). In addition, Welch and Nuttall observed the bacilli grew anaerobically as
small colonies were present in the bottom two-thirds (oxygen depleted region) of an agar
tube, while the upper third (microaerobic) had no growth. Based on these observations,
they arrived at the name Bacillus aerogenes capsulatus (Welch and Nuttall, 1892). Over
time the bacterium became known as Bacillus welchii and Clostridium welchii, before
being renamed as Clostridium perfringens (Dembek, 2008).

1.2 MORPHOLOGY AND CLASSIFICATION OF CLOSTRIDIUM
Clostridium is a genus in the class Clostridia and the phylum Firmicutes. This
genus consists of more than 100 species; however, the four species most commonly
associated with human and animal disease are C. perfringens, C. tetani, C. botulinum and
C. difficile. Clostridium spp. are non-motile, Gram positive rods that grow anaerobically
and form spores (Uzal et al., 2016; Vasanthakumari, 2007). A single bacterium of C.
perfringens averages 0.6-2 µm in diameter by 1.3-6 µm in length and can be found in
pairs, single rods and small clusters (Uzal et al., 2016; Vasanthakumari, 2007). After 24
hours of growth under anaerobic conditions, C. perfringens colonies are smooth, circular,
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semi-translucent and approximately 2-5 mm in diameter (Uzal et al., 2016). Bacteria
categorized as anaerobes are incapable of growing in the presence of oxygen and can be
further classified as either strict anaerobes or aerotolerant anaerobes. Strict anaerobes, do
not live when exposed to oxygen, while aerotolerant anaerobes grow anaerobically but
can survive being exposed to oxygen (Uzal et al., 2016). C. perfringens has the ability to
survive under-micro-aerobic conditions, thus being classified as an aerotolerant anaerobe.
C. perfringens produces four major toxins that are essential for virulence. In
addition to being essential for virulence, the four major toxins of C. perfringens are used
to classify the bacteria into five toxinotypes A, B, C, D and E (Table 1). The four toxins
being: alpha (CPA), beta (CPB), epsilon (ETX) and iota (ITX) (Uzal et al., 2014). CPA
causes damage to many cell types, including erythrocytes, hepatocytes and myocytes.
CPA disrupts the cell surface phospholipid bilayers by cleavage of the phosphorylcholine
head groups, which disrupts the cell membrane causing necrosis and cell lysis (Li et al.,
2013). In livestock, cellular pore formation is a result of CPB toxin oligomerization on
the cell surface via lipid rafts. This causes an efflux of potassium ions and an influx of
sodium and chloride ions causing an increase in turgor pressure leading to cell lysis
(Geny and Popoff, 2006). ETX is also a pore forming toxin that affects brain, lung and
smooth muscle cells. A remarkable feature of ETX is the ability to selectively cause
death of oligodendrocytes without killing astrocytes, microglia or neurons of the central
nervous system (Linden et al., 2015). ITX is an A-B toxin consisting of the enzymatic
protein Ia and the cell surface binding protein Ib. Individually, the two components are
inactive but together cause enterotoxemia by increasing intestinal cell permeability and
cell rounding and death through ADP-ribosylation of G-actin (Sakurai et al., 2009).
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These toxins contribute to the diversity of species and tissues affected by C. perfringens
strains.

Table 1: C. perfringens toxinotype classification based on the presence or absence of the
four major toxin classes.
Type
Alpha (α)
A
+
B
+
C
+
D
+
E
+

Beta (β)
+
+
-

Epsilon (ε)
+
+
-

Iota (ι)
+

1.3 INFECTIONS CAUSED BY C. PERFRINGENS
Each C. perfringens toxinotype is associated with specific human and/or animal
diseases highlighting the versatility of this bacterium (Smedley et al., 2004; Uzal et al.,
2014). C. perfringens type A and type C are the two toxinotypes associated with both
human and animal disease. In humans, type A strains can induce food poisoning, nonfoodborne gastrointestinal disease and gas gangrene mainly due to the effect of CPA.
Type C strain infections in humans cause necrotic enteritis also known as pigbel. This is
an intestinal infection causing abdominal pain, vomiting and in severe cases death due to
CPB toxemia (Uzal et al., 2014; Uzal and McClane, 2011). In addition to human
infections, all C. perfringens toxinotypes can infect adult animals; however, these
infections are predominantly seen in neonates that have not established normal gut flora.
C. perfringens type A causes gas gangrene infections in cattle, sheep, goats and horses
that are similar to human infections. When type C infections occur in livestock species,
they cause necrotic enteritis and enterotoxemia (Uzal and McClane, 2011; Uzal et al.,

5
2010). Necrotic enteritis is one of the most important diseases of C. perfringens type C,
which is found in goats, cattle, pigs and horses.
The CPB toxin produced by C. perfringens type C can cause a neurological
disease that includes rigid paralysis, also known as opisthotonos, where the animals
demonstrate backward arching of the head, neck and spine (Nagahama et al., 2015;
Tweten, 2001). This neurological involvement is due to the toxin being able to move into
circulation and cross the blood brain barrier. In adult sheep, the condition known as
struck refers to a type C disease. The presentation of struck within sheep is described as
if they have been struck by lightning.
Characteristics of necrotic enteritis are hemorrhagic mucosal ulceration or
superficial mucosal necrosis of the small intestine, which is often followed by death or
acute neurological signs (Smedley et al., 2004). The other toxinotypes, such as type B
which produces CPA, CPB and ETX causes hemorrhagic dysentery in sheep.
Enterotoxemia of sheep, goats and cattle and enteritis in dogs, cattle and pigs are caused
by type D (ETX) and type E (ITX) respectively (Uzal et al., 2014). Each of the
Clostridial toxinotypes has a specific pathogenesis; however, since this thesis focuses on
the development of a CPB analytical assay, only C. perfringens type C will be further
discussed.

1.4 PATHOGENESIS OF C. PERFRINGENS TYPE C
Clostridium perfringens is found in soils, feces and human and animal digestive
tracts. For infections to occur in neonates, C. perfringens must first gain entry into the
host digestive tract. The normal intestinal microbiota takes time to develop a stable
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community in newborns, which makes them highly susceptible to colonization by type C
strains, resulting in disease in young animals (i.e., exposure 24 – 48 hours after birth)
(Uzal et al., 2014; Uzal and McClane, 2011). Transmission occurs via the fecal oral
route by suckling contaminated teats, ingesting colostrum during nursing from mothers
who carry the bacterium, licking contaminated objects in the surroundings, or by coming
into close contact with contaminated fecal material from infected animals (Niilo, 1988).
Susceptibility is believed to be due to low or absent proteinase activity in the neonate,
and the trypsin inhibitors in colostrum may contribute to this problem (Uzal et al., 2016).
Once the development of normal flora is established in young animals, opportunistic
infections by toxinotype C bacteria are greatly reduced (Tweten, 2001). While type C
strain infections primarily occur in infant animals, adult animals are also susceptible to
infections. This is likely due to gastrointestinal factors that affect an increase in the pH
of the stomach, which favors growth, colonization and toxin production in the intestine.
A diet high in foods with trypsin inhibitors such as soybeans may contribute to the
susceptibility of adult animals (Uzal et al., 2016). Another factor contributing to type C
strain infections are unvaccinated herds, where the mortality rate can be greater than 50%
(Uzal and McClane, 2011).
Once C. perfringens toxinotype C bacteria reach the intestine, they adhere to the
epithelium of the small intestine and secrete alpha and beta toxins causing necrosis. The
damage caused by CPB allows other toxins (i.e., CPA) to be introduced into the host’s
blood (Nagahama et al., 2015). Circulating CPA exacerbates the destruction of epithelial
cells and permits invasion of bacteria. All of this causes a cascade effect, which leads to
increased toxin production, cellular necrosis, hemorrhage and death (Nagahama et al.,
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2015; Niilo, 1988). These observations contribute to the belief that CPB is the most
important toxin for virulence (Gurtner et al., 2010; Sayeed et al., 2008; Uzal et al., 2009;
Vidal et al., 2008).

1.5 EVIDENCE FOR THE INVOLVEMENT OF BETA TOXIN
A number of animal models have been used to determine the function of CPB as a
virulence factor. When animals and humans were given crude beta toxoid, they were
protected against strain type C infections suggesting that CPB was an essential virulence
factor (Walker et al., 1979). A mouse model using intravenous injection of CPB from
type C culture supernatants also demonstrated that CPB was important for virulence
(Fisher et al., 2006). Lethality of CPB is inhibited by monoclonal antibodies to CPB,
protecting mice from a lethal intravenous challenge; however, lethality was not
attenuated in mice with a monoclonal antibody to CPA (Fisher et al., 2006; Uzal and
McClane, 2011). In addition, studies using cpb null mutants to infect mice, rabbit and
goats in an intestinal loop model demonstrated that cpb mutants are attenuated in
virulence relative to the wild-type strains (Sayeed et al., 2008). Taken together, CPB is
essential for virulence in toxinotype C infections.

1.6 CHARACTERIZATION OF BETA TOXIN
Bacterial toxins are generally classified as either endotoxins or exotoxins.
Endotoxins are associated with the cell envelope of Gram negative bacteria which have a
lipopolysaccharide complex associated with the outer membrane. Exotoxins are proteins
that are secreted by many Gram positive and Gram negative bacteria. A subclass of
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exotoxin is enterotoxins, which target the intestine and are commonly pore-forming
toxins that disrupt cell membranes. The CPB exists as a monomer or oligomer and is
defined as an exotoxin that forms pores (Popoff, 2014; Shatursky et al., 2000). The
monomer is the toxic form and can readily convert to the nontoxic oligomer form in vitro
(Sakurai and Nagahama, 2006); however, the oligomeric form is unable to dissociate
back into the monomeric form. The 35 kDa CPB is secreted during the post-exponential
growth phase and is known to be susceptible to proteolytic and heat inactivation, but not
by low pH (Sakurai and Duncan, 1978; Uzal and McClane, 2011; Vidal et al., 2008).
The cpb gene is carried on a virulence plasmid found in type C isolates and codes for a
336 amino acid protein containing a 27 amino acid leader sequence that is cleaved to
form the mature beta toxin protein (Hunter et al., 1993; Nagahama et al., 2015; Sakurai et
al., 2004; Uzal et al., 2010). In susceptible cell lines, such as primary porcine cells,
human umbilical vein endothelial cells (HUVEC), and human leukemia cells (HL-60
cells), CPB intoxication results in swelling and cell lysis (Nagahama et al., 2015; Uzal
and McClane, 2011).

1.7 MODE OF ACTION OF BETA TOXIN
The C. perfringens type C beta toxin is a pore forming toxin that forms
multimeric complexes in HUVEC cell membranes (Steinthorsdottir et al., 2000) and
cation-selective pores in phospholipid bilayers (Shatursky et al., 2000). In addition, CPB
induces swelling and cell lysis in the human leukemia cell line HL-60 (Nagahama et al.,
2003). One hypothesis is that CPB monomers (35 kDa) are incorporated into susceptible
membranes and oligomerize into ~228 kDa hexamers or heptamers to form a
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transmembrane pore (Smedley et al., 2004). More recently, it was postulated that CPB
monomers recognized an unidentified receptor on the cell surface, then oligomerize to
form a prepore and the prepore is inserted into the lipid bilayer to form a pore (Geny and
Popoff, 2006; Popoff, 2014). Irrespective of the mechanism, CPB induced cell death is
initiated by the formation of pores that cause an efflux of K+ and Ca2+ with a concomitant
influx of Na+ and Cl- ions resulting in cell lysis (Autheman et al., 2013; Nagahama et al.,
2003; Uzal et al., 2014). To prevent infections in animals caused by the pore-forming
CPB, prophylactic vaccination has mostly proven to be efficacious in preventing type C
disease.

1.8 VACCINES
Commercially available C. perfringens type C vaccines for veterinary use contain
chemically inactivated cultures where the toxin is now referred to as toxoid of type C
strains, or in combination with types A, B or D strains. These inactivated cultures
produce an antigenic response to the type C CPB despite detoxification of the antigen.
The use of pure or mixed cultures concomitant with the production of extraneous proteins
has created a situation where the efficacy of vaccines is highly variable, and has
increased the demand for more reproducible and quantifiable antigens such as
recombinant proteins.
The variability of vaccine preparations can be seen in a field trial for Per-Cporc®. In this trial, sows were given Per-C-porc® a type C toxoid vaccine, at a breeding
facility that had experienced significant losses of piglets due to the C. perfringens type C
disease. Prior to vaccination, three batches of the Per-C-porc® vaccines were tested in
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accordance with the European Pharmacopoeia, the same requirements as the Code of
Federal Regulations number 9 (9CFR) USDA, in which there has to be at least 10
international units (IU) of beta antitoxin per mL of rabbit serum (Springer and Selbitz,
1999). The results from the in vivo efficacy testing of the vaccine batches revealed that
all three batches fulfilled the regulatory requirements, however the mean titer values
varied greatly with a range of 17.14 to 98.23 IU beta antitoxin per mL in rabbit serum
(Springer and Selbitz, 1999). The titer fluctuation was due to inconstancies in antigen
production, which resulted in different yields of toxin during fermentation that affected
performance in efficacy testing. The type C vaccine with the lowest IU beta antitoxin per
mL rabbit serum result was used to vaccinate the sows. During this study, there was a
slight decrease in piglet loss when the sows were vaccinated and their piglets were
administered benzylpenicillin potassium within the first three days of birth. The need for
antibiotic use shows the type C toxoid vaccines are not fully protective and antibiotics are
needed to protect piglets from C. perfringens type C disease (Springer and Selbitz, 1999).
The variability in manufacturing and the need for antibiotics highlighted the need for
more efficacious vaccine strategies (Springer and Selbitz, 1999).
Other vaccine approaches include the use of recombinant proteins expressed in
Escherichia coli and harvested from solubilized inclusion bodies are used as immunogens
to vaccinate animals (Zeng et al., 2011). The vaccines had either monovalent
recombinant α-toxin (CPA), a fusion protein of β2/β1 (CPB2B1), a trivalent fusion
protein consisting of α/β2/β1-toxins (CPAB2B1) or a cocktail CPA plus CPB2B1. These
recombinant protein vaccines were administered to mice, cows and sows. In a mouse
toxin challenge model, mice were challenged at either 14 days or at 42 days post-
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vaccination. Vaccine groups with CPA plus CPB2B1 or the multivalent CPAB2B1 had
greater survival rates, even at day 42, than mice vaccinated with the monovalent CPA;
suggesting that recombinant toxoids are viable vaccine candidates with extended efficacy
(Zeng et al., 2011). Histopathological examination of the mice intestines revealed that
vaccinated mice, no matter the treatment, did not have gross pathological changes in
contrast to the control mice. In addition to pathology, antibody titers of serum from
immunized mice, sows and cows and the colostrum from immunized sows and cows were
also examined. The highest neutralizing antibody titers were generated in mice but the
sera and colostrum of sows and cows also had detectable titers. Neutralizing antibodies
in the colostrum implies the recombinant toxoids are able to stimulate maternal
antibodies for protection of their offspring (Zeng et al., 2011). Immunization with
CPB2B1 or CPA plus CPB2B1 produced greater neutralizing antibody titers than did the
CPA monovalent vaccine. In addition, fusion proteins increase the level of safety and
effectiveness relative to the use of whole-cell bacterial vaccines, as the numerous
extraneous proteins are eliminated (Zeng et al., 2011).
In addition to the toxin cocktail mentioned above, a recombinant C. perfringens
type C beta toxoid (rBT) produced in E. coli and purified from inclusion bodies was
evaluated as a vaccine candidate (Milach et al., 2012). Potency testing of this vaccine
was performed according to the 9CFR USDA and EP and was shown to be non-toxic
through evaluation of the lethal dose (LD50) for the recombinant compared to the native
beta toxin. This group showed that 100 µg of rBT inoculated intravenously did not
exhibit any clinical signs of toxicity, as compared to 0.4 µg per kg LD50 for the wild-type
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beta toxin. In addition, the rBT was able to induce rabbit serum with 14 IU beta antitoxin
per mL, which is superior to a vaccine using the wild-type toxins.
Vaccines using recombinant proteins/toxoids are considered to be more stable,
safer and efficacious, and have the potential to be new candidates for commercial
vaccines (Salvarani et al., 2013). This is illustrated by a study where pregnant sows were
vaccinated twice with a bivalent vaccine consisting of C. perfringens alpha (rTA) and
beta (rTB) recombinant toxoids (Salvarani et al., 2013). Protective antibody titers of antialpha toxin (~6.0 IU per mL) and anti-beta toxin (~14.5 IU per mL) were produced.
Importantly, the antibody titers to alpha and beta toxins were higher than the USDA
required minimums (Salvarani et al., 2013). The litters from vaccinated sows also
exhibited titers of neutralizing antibodies to alpha and beta toxins by passive
immunization through colostrum. The litters had an alpha antitoxin titer of ~4.2 IU per
mL and a beta antitoxin titer of ~10.9 IU per mL, which also met the USDA required
minimum standard (Salvarani et al., 2013). These data demonstrate the vaccine and
immunization strategy elicited a maternal immune response comparable to other vaccine
formulations (Matisheck and McGinley, 1986; Salvarani et al., 2013). Overall, using
recombinant toxoids may be less labor intensive and safer to produce, and can potentially
reduce the costs of manufacturing the vaccines.
Immunogenic, non-toxin proteins were identified using serum from C.
perfringens infected birds. These two non-toxin, highly immunogenic proteins were
pyruvate: ferredoxin oxidoreducate (PFO) and elongation factor-Tu (EF-Tu) (Jang et al.,
2012). PFO is an enzyme that catalyzes the conversion of pyruvate into acetyl-CoA,
while EF-Tu facilitates binding of charged tRNAs to the A-site of ribosomes. These
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proteins were cloned, over-expressed in E. coli, and used in infection protection studies.
The efficacies of these proteins were compared to two different recombinant toxins by
assessing the levels of protection achieved in a C. perfringens disease infection model.
The cloned toxins used in the challenge were the C. perfringens alpha toxin and NetB, a
necrotic enteritis B-like toxin. All four proteins were mixed individually with a
commercial oil-in-water adjuvant (Jang et al., 2012) and tested for their ability to protect
chickens against infections with virulent cultures of Eimeria maxima and C. perfringens.
In this model, the first vaccination occurred in chicks one day of age and the second
vaccination occurred when the birds were seven days old. At 14 days of age, the birds
received a live culture of E. maxima by oral lavage (Jang et al., 2012). Four days after
administering the E. maxima culture, the birds were orally given live C. perfringens
cultures and 20 days post-hatch the serum antibodies were measured. Increased antibody
titers and weight gain were observed in birds vaccinated with NetB and PFO.
Additionally, the NetB and PFO recombinant protein vaccines were more efficacious
against the double challenge of E. maxima and C. perfringens challenge than was the
alpha toxin and EF-Tu recombinant protein vaccines (Jang et al., 2012). However, alpha
toxin and EF-Tu vaccinates were efficacious in comparison to the controls. This data
highlights a different approach in selecting non-toxin vaccine candidates.
While much of the current research for development for C. perfringens type C
vaccines seems to be progressing toward the use of recombinants, these will not replace
current commercial vaccines in the near future; hence, in vitro assays to detect vaccine
components are necessary to facilitate production and regulatory compliance.
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1.9 CURRENT ASSAYS – IN VIVO AND IN VITRO
Prevention of C. perfringens type C infections relies heavily on vaccination with
inactivated whole bacteria. For vaccines to be efficacious, they should be able to elicit a
protective immune response in the host animal. The commercially available C.
perfringens type C vaccines produce neutralizing antibodies against the clostridial toxins.
Production needs and regulatory requirements necessitate in-process testing for antigen
production. Currently, C. perfringens type C toxin materials are assayed using an in vivo
test method, known as the L+ test. In this assay, the toxin product is diluted and
combined with a known amount of anti-toxin antibody, which is specific to the beta
toxin. The different dilutions are intravenously administered to five mice for each
dilution and the dilution which is lethal to 80% of the mice determines the potency
concentration. The concentration at the specific dilution is further used to calculate the
amount of non-toxin antigen to formulate into final vaccine.
The current required test for final vaccine potency involves the use of mice and
rabbits and is mandated in the 9CFR USDA guidelines and EP monograph (United States
Department of Agriculture, 2017a) . According to the USDA guidelines, the in vivo test
requires a minimum of eight rabbits subcutaneously administered with one half of the
largest recommended dose, or less, based on the target host species. A second injection is
given 20-23 days following the first administration. All surviving rabbits after 14-17
days post vaccination are bled, the serum pooled and the serum tested for antitoxin levels.
As described in the 9CFR 113.111 (United States Department of Agriculture, 2017a), the
antitoxin neutralizing antibody level is determined through a dilution series using an
antitoxin standard. The neutralizing antibody levels are assessed against C. perfringens
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beta toxin and are estimated in vivo using a mouse neutralization test (Ebert et al., 1999).
To meet the prescribed standard, vaccines must have at least 10 IU of standard beta
antitoxin per milliliter of rabbit serum. The use of animals in these validated assays has
led to a desire to develop new assays that reduce the number of animals required.
The development of in vitro assays would be cost effective by greatly reducing
the number of animals used each year. Efforts to reduce the number of animals required
for toxin validation have led to eliminating the use of mice; however, rabbits are still
required for sera generation (Ebert et al., 1999). While it is desirable to use only in vitro
assays, these assays must be comparable to in vivo tests and to date only proof-ofprinciple studies have been performed, and these assays must be validated and accepted
by the USDA and EP (Redhead et al., 2011). In summary, producing the toxoid is labor
intensive and potency testing is time consuming and requires the use of animals. While
work is being done to develop new vaccines against CPB, improvements in the potency
testing are needed.
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CHAPTER II

ABSTRACT
Clostridium perfringens is a Gram positive anaerobic rod and a major cause of
enteric disease in both humans and livestock. There are five C. perfringens toxinotypes,
(i.e., A, B, C, D and E) that are classified based on the type of toxins each produces. The
focus of this work is on the beta toxin produced by C. perfringens type C. The primary
virulence determinant of C. perfringens type C is the beta toxin, which causes necrotic
enteritis in neonatal animals. Fortunately, cattle and pig vaccines directed against C.
perfringens toxins are efficacious. Production of a commercial vaccine requires not only
an efficacious antigen, but also testing methods for quantifying antigens and potency
determination of the finished vaccine. These methods are performed in vivo according to
the Code of Federal Regulations number 9 (9CFR) United States Department of
Agriculture (USDA) and European Pharmacopeia (EP) monograph guidelines.
Currently, there are limited in vitro alternatives to assessing C. perfringens type C beta
toxin in fermentation media or final vaccine potency. With the generation of polyclonal
and monoclonal antibody reagents, an in vitro method could be developed to measure C.
perfringens type C toxoid material independent of laboratory animals implementing the
principles of the 3Rs (replacement, reduction and refinement).

2.1 INTRODUCTION
This work focuses on filling the need for an in vitro method to measure the C.
perfringens type C toxoid, which will help reduce the use of laboratory animals and
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facilitate vaccine production. An enzyme-linked immunosorbent assay (ELISA) was
developed to quantitate the C. perfringens type C beta toxoid from cultivation media.
This could improve accuracy in formulating vaccines in contrast to the in vivo method of
estimating the amount of toxin. The necessary reagents were developed and the assay
format assessed as shown in the following section. In addition, results from the
developed ELISA are presented.

2.2 MATERIALS AND METHODS
2.2.1 BACTERIAL CULTIVATION CONDITIONS
C. perfringens type C was grown in a 10 liter Celligen BLU single use fermenter
containing media components of soy peptone, casein hydrolysate (Tryptone), yeast
extract, antifoam and dextrose. Actively growing culture was aseptically added at 20
mL/L to the fermenter and incubated at 36°C ± 2°C for approximately 3-6 hours with pH
maintained between 7.0 – 7.5.

2.2.2 TOXIN AND TOXOID PREPARATION
For toxin preparation, the fermentation culture was centrifuged at 15,000g using a
Sorvall RC 6+ centrifuge for 30 minutes at 4°C; supernatants were pooled and cell pellets
discarded. The supernatant was passed through a Sterile MidiCap Sartopore 2 filtration
unit containing a 0.45 + 0.2 μm membrane.
For toxoid preparation, the fermentation culture was chemically inactivated with
formaldehyde prior to centrifugation at 15,000g using a Sorvall RC 6+ centrifuge for 30
minutes at 4°C; supernatants were pooled and cell pellets discarded. The supernatant was
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passed through a Sterile MidiCap Sartopore 2 filtration unit containing a 0.45 + 0.2 μm
membrane.
A control of C. perfringens type A toxoid culture medium was provided by the
bacterial processing group at Zoetis Inc., Lincoln, NE.

2.2.3 ISOLATION OF MONOCLONAL ANTIBODIES
All in vivo work was conducted after ethical review and in compliance with local,
national and international guidance. Specific pathogen-free BALB/c mice (17 to 20 g; 3
mice; no gender was specified) were immunized according to the Maine Biotechnology
Services, Inc. (MBS) Rapid Immunization Multiple Sites (RIMMS) protocol. Mice were
immunized five times within the 20 day period at multiple sites; each injection time point
used 0.5mL of C. perfringens type C toxoid adjuvanted vaccine. At day 20, blood was
collected and serum screened by ELISA to determine the specific antibody titer. Based
on the screening results, the mice received an additional boost following the test bleed
and a second test bleed was taken 10 days after the last boost. Based on the test bleed
screen, MBS then selected one mouse for fusion that had the highest anti-CPB titer. The
spleen was dissected from the mouse and the splenocytes were fused with SP2/0
myeloma cells to create hybridomas. The fused cells were cultured and supernatants
were evaluated for antibody production. Hybridoma supernatants were assessed for CPB
toxoid specificity by an indirect ELISA. There were 41 type C toxoid specific clones that
were selected. These hybridoma positive culture supernatants were further processed
through three rounds of subcloning by limiting dilution.
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A mouse hybridoma secreting a beta toxin specific monoclonal antibody was
obtained from the Center for Veterinary Biologics (CVB) Ames, IA courtesy of Dr. Paul
Hauer. This monoclonal antibody detected the 38 kDa protein band associated with CPB
toxoid on western blot. The CVB monoclonal antibody was subsequently used as a
positive control on confirmatory assays such as western blot, ELISA and neutralization
assay.

2.2.4 POLYCLONAL ANTIBODIES
Goat anti-C. perfringens Type C toxoid polyclonal antibodies were provided by
from the Laboratory Sciences group at Zoetis Inc., Kalamazoo, MI. All in vivo work was
conducted after ethical review and in compliance with local, national, and international
guidance.

2.2.5 INDIRECT ELISA
Indirect ELISA was used to screen hybridoma supernatants for antibodies from
MBS. To determine if the hybridoma supernatants had antibodies to C. perfringens type
C toxoid only, a positive indirect ELISA was used with a type C antigen coating and a
negative indirect ELISA performed with C. perfringens type A antigen coated on the
assay plates. C. perfringens type C toxoid antigen was diluted in 0.01 M borate buffer
(sodium tetraborate in purified water, pH 9.0 – 9.2) for a final concentration of 300 µg
antigen per 100 µL buffer. Polystyrene flat bottom 96-well plates (Nunc MaxiSorp) were
incubated overnight at 4°C with a volume of 100 µL per well of diluted antigen. The
next day, plates were washed three times with 0.1 M phosphate buffered saline
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containing 0.05% tween 20 (PBST). The plates were blocked by adding 200 µL/well of
1% casein sodium in PBST and then incubated at 37°C ± 2°C for 1 hour. After blocking,
the plates were washed three times with PBST followed by 50 µL of each hybridoma
supernatant dispensed into their respective well on the plate. The plates were covered
and incubated for 60 minutes at 37°C ± 2°C. Post incubation, plates were washed three
times with PBST followed by the addition of 50 µL/well of diluted peroxidase conjugated
goat anti-mouse IgG heavy and light chain (Jackson ImmunoResearch). The peroxidase
conjugate was diluted in 1% casein sodium in PBST at 1:3,000 dilution and then
incubated for 60 minutes at 37°C ± 2°C. Following incubation, the plates were washed
three times and 50 µL/well of ABTS (2, 2'-Azino-di-3-ethylbenzthiazoline-6-sulfonate)
peroxidase substrate (Kirkgaard & Perry Laboratories) was added and the plates were
incubated at room temperature for 15 to 20 minutes. The reaction of the conjugated
enzyme with the ABTS substrate produces a greenish color. The optical density (OD) of
each well is determined using values of 405 nm minus 490 nm as determined on a Vmax
kinetic microplate reader (Molecular Devices) and the SoftMax Pro software 6.3. The
same conditions and reagent concentrations were used to determine if the hybridoma
supernatants had antibody present to C. perfringens type A toxoid for the negative
indirect ELISA screen. Hybridomas were selected using the criteria of the well in the
positive assay having an absorbance of ≥ 0.08 and the corresponding well in the negative
assay having an absorbance of ≤ 0.05.

21
2.2.6 SDS-PAGE AND WESTERN BLOTTING
Proteins present in the C. perfringens type C beta toxin preparation were
visualized on a 4-12% Bis-Tris SDS-PAGE gel using a GelCode Blue Safe Protein
coomassie blue stain (Pierce Biotechnology). For western blot analysis, proteins from the
gel were transferred to a nitrocellulose membrane using the iBlot™ 2 gel transfer device
and iBlot™ 2 Transfer Stacks containing the nitrocellulose membranes (Invitrogen).
Non-specific binding was blocked using 0.5% gelatin (from cold water fish skin) in
PBST. This was followed by incubation at room temperature with anti-CPB antibodies.
The blots were washed with 0.05% tween 20 in PBS and then incubated for 30 minutes at
room temperature with peroxidase conjugated goat anti-mouse IgG H+L (Jackson
ImmunoResearch). Membranes were developed with TMB (3, 3’, 5, 5’–
Tetramethylbenzidine) peroxidase substrate 3-component system (Kirkgaard & Perry
Laboratories).

2.2.7 NEUTRALIZATION ASSAY
The neutralization assay was used to assess the ability of antibodies to neutralize
the C. perfringens type C beta toxin. Vero cells, derived from the kidney of normal adult
African green monkey, were cultivated in Eagles Modified Essential Medium (EMEM)
(Gibco, Calsbad, CA) supplemented with 5% fetal bovine serum (FBS) (Atlanta
Biologicals, Lawrenceville, GA) and maintained in a 37˚C humidified chamber with 5%
CO2. Vero cells were seeded in 96-well plates and grown to a confluent monolayer with
a cell density of 125,000 cells per well. The antibody samples were diluted either 1:2 or
1:4 in EMEM medium. Two-fold serial dilutions were made across the dilution plate,
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leaving the last two columns for positive and negative control wells (100 µL/well).
Clostridium perfringens type C beta toxin was added to the dilution plate containing the
diluted antibody samples (100 µL/well). The dilution plate was incubated for 2 hours at
37°C ± 2°C with 5% CO2. After incubation, 200 µL of antibody/toxin material from the
dilution plate was transferred to the actively growing Vero cell plate. Vero plates were
then incubated for 2 days at 37°C ± 2°C with 5% CO2. Following incubation, cells were
assessed under a microscope for cytopathic effect (CPE). Wells having intact cells in a
confluent monolayer indicate the antibody neutralized the beta toxin challenge. Wells
lacking a monolayer indicate the antibody was unable to neutralize the beta toxin,
resulting in CPE on the cells.

2.2.8 CHECKERBOARD ASSAY
A checkerboard assay method was used to determine the optimal dilutions of the
capture (polyclonal) and indicator (monoclonal) antibodies for the in-process assay to
measure C. perfringens type C toxoid. A checkerboard pattern was obtained by using a
polystyrene flat bottom 96-well plate with the capture antibody dilutions down the y-axis
(row A through row H) and the indicator antibody dilutions were along the x-axis
(column 1 through column 12). Each plate was coated with capture antibody diluted in
0.01 M borate buffer; with the starting dilution of the capture antibody on the plate in row
A being 1:250 and followed by two-fold serial dilution from row A through H and the
plates were then incubated overnight at 4°C. Plates were washed the next day three times
with PBST and then blocked with 1% casein sodium in PBST (200 µL/well) and
incubated at 37°C ± 2°C for 1 hour. After blocking and washing the plates, C.
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perfringens type C antigen was added to each of the wells at a constant concentration,
300 µg antigen per 200 µL per well diluted in 1% casein sodium in PBST. The plates
were covered and incubated for 1 hour at 37°C ± 2°C. Post incubation period, the plates
were washed three times with PBST and the indicator antibody diluted in 1% casein
sodium was added to each plate. The starting dilution of the indicator antibody on the
plate in column 1 was 1:250 and followed by two-fold serial dilution from columns 1
through 12. The plates were covered and incubated for 1 hour at 37°C ± 2°C. Post
incubation, plates were washed three times with PBST, followed by the addition of 100
µL/well of a 1:2,000 dilution of the conjugate antibody (i.e., peroxidase conjugated goat
anti-mouse) diluted in 1% casein sodium in PBST and then incubated for 1 hour at 37°C
± 2°C. Following incubation, the plates were washed three times and ABTS peroxidase
substrate was added (50 µL/well), and the plates were incubated at room temperature for
15 to 20 minutes. The plates were read at 405 minus 490 nm with Vmax kinetic
microplate reader (Molecular Devices) and the SoftMax Pro software 6.3. The average
OD were plotted for both capture and indicator antibodies to determine the optimal
dilutions.

2.2.9 SANDWICH ELISA
A sandwich ELISA method was used to develop the in-process assay for
measuring C. perfringens type C toxoid. Goat anti-C. perfringens type C toxoid
polyclonal antibody was diluted in 0.01 M borate buffer and dispensed onto polystyrene
flat bottom 96-well plates (Nunc MaxiSorp) that were incubated overnight at 4°C with
diluted antibody (100 µL/well). The next day, plates were washed three times with 0.1 M
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PBST and blocked with 1% casein sodium in PBST (200 µL/well) and incubated at 37°C
± 2°C for 1 hour. After blocking, plates were washed three times with PBST followed by
the addition of C. perfringens type C toxoid samples. The plates were covered and
incubated for 1 hour at 37°C ± 2°C. Post-incubation, plates were washed three times
with PBST, followed by the addition of anti-C. perfringens type C monoclonal antibody
diluted in 1% casein sodium in PBST (100 µL/well). The plates were covered and
incubated for 1 hour at 37°C ± 2°C. Post-incubation, plates were washed three times
with PBST, followed by the addition of 100 µL/well of diluted peroxidase conjugated
goat anti-mouse IgG H+L (Jackson ImmunoResearch). The conjugate was diluted in 1%
casein sodium in PBST at 1:2,000 dilution and then incubated for 1 hour at 37°C ± 2°C.
Following incubation, the plates were washed three times and 50 µL/well of ABTS
peroxidase substrate (Kirkgaard & Perry Laboratories) was added, and the plates
incubated at room temperature for 15 to 20 minutes. The OD values at 405 nm minus
490 nm were determined using a Vmax kinetic microplate reader (Molecular Devices)
and the SoftMax Pro software 6.3.

2.2.10 IN-PROCESS ELISA
The following describes the developed in-process ELISA method for measuring
C. perfringens type C toxoid. The polyclonal capture antibody, anti-C. perfringens beta
goat 31, was diluted in 0.01 M borate buffer and dispensed onto polystyrene flat bottom
96-well plates (Nunc MaxiSorp) that were incubated overnight at 4°C with diluted
antibody (100 µL/well). The next day, plates were washed three times with 0.1 M PBST
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and blocked with 1% casein sodium in PBST (200 µL/well) and incubated at 37°C ± 2°C
for 1 hour.
During the blocking step, the reference, positive control and test samples are
vortexed for 15 seconds (3 by 5 seconds) at maximum vortex speed. Then dilutions of
reference, positive control and test articles are prepared by making a 1:54 dilution in 1%
casein sodium in PBST. In a dilution plate, 150 µL of 1% casein sodium in PBST is
dispensed into each well column 2 – 11 and rows C – G (Fig.1). In row B, 300 µL of
1:54 diluted reference, positive control and each test article is added to wells as labeled
and shown in Figure 1. Two-fold dilutions are preformed down the plate by mixing the
samples in row B and transferring 150 µL to row C. Changing pipette tips between rows
and repeated through row G.
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Fig. 1: In-process assay 96-well plate configuration. Ref (Reference), + (Positive
Control), T01-03 are test samples.
The blocked plates were washed three times with PBST and 100 µL from the
dilution plates was transferred to blocked plates as follows; beginning in row G through
row B, material is transferred to the respective wells. The outer wells on the plate (Fig.
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1) receive 100 µL of PBST. The plates are covered and incubated at 37°C ± 2°C for 1
hour. Post incubation, plates were washed three times with PBST, followed by the
addition of indicator antibody, mouse anti-C. perfringens type C toxoid monoclonal
antibody (mAb 23) diluted 1:2,000 in 1% casein sodium in PBST (100 µL/well). The
plates were covered and incubated at 37°C ± 2°C for 1 hour and after incubation the
plates were washed three times with PBST. The peroxidase conjugate antibody, goat
anti-mouse, was diluted at 1:2,000 in 1% casein sodium in PBST and added at 100 µL
per well. The plates were covered and incubated at 37°C ± 2°C for 1 hour and after
incubation the plates were washed three times with PBST. After the final washing step,
50 µL/well of ABTS peroxidase substrate was added to all wells on the plates. The plates
were read at 405 nm minus 490 nm with Vmax kinetic microplate reader (Molecular
Devices) and the SoftMax Pro software 6.3. with five second shake pre-read targeting a ≥
0.8 OD for the first dilution of the reference (average of wells B2 and B7 as shown in
Figure 1).

2.3 RESULTS
2.3.1 CHARACTERIZATION OF POLYCLONAL ANTIBODIES
Two polyclonal antibodies were provided by Zoetis Inc.; specifically, anti-C.
perfringens beta goat 11 and anti-C. perfringens beta goat 31. The two polyclonal
antibodies were characterized by western blot analysis to confirm recognition of the 38
kDa beta protein. Both goat 11 and 31 polyclonals recognized the 38 kDa protein band
of C. perfringens type C (Fig. 2). As expected, polyclonal antibodies bound to a band at
38 kDa that corresponds to the CVB beta toxin positive control included on the western
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blot. To assess the ability of the polyclonal antibodies to neutralize beta toxin, their
neutralizing activity was evaluated (Table 2). Anti-C. perfringens beta goat 31 had slight
neutralizing activity, while anti-C. perfringens beta goat 11 lacked neutralizing activity.
Overall, neither of the polyclonal antibodies had pronounced neutralizing capabilities;
however, the antibodies only need to capture the beta toxoid through epitope binding and
neutralizing capability is not required. To assess their potential utility in an ELISA, the
polyclonal antibodies were evaluated using an indirect ELISA (Fig. 3). The assay
distinguished the differences between the antibodies where anti-C. perfringens beta goat
31 bound the C. perfringens type C toxoid material but anti-C. perfringens beta goat 11
did not. For this reason, the goat 31 anti- C. perfringens beta toxoid antibody was
selected as the polyclonal antibody to be used as the capture for developing an in-process
assay to measure type C material.
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Fig. 2: Western blot analysis depicting C. perfringens type C beta toxin specific protein
binding by polyclonal antibodies 31 and 11. Lane 1 molecular weight marker. Lane 2
negative goat serum control, 1:4,000 dilution. Lane 3 positive control monoclonal to beta
from the Center for Veterinary Biologics (CVB), 1:80,000 dilution. Lane 4 through 6 are
anti-C. perfringens beta goat 31 at 1:10,000, 1:20,000 and 1:40,000 dilutions respectfully.
Lane 7 through 9 are anti-C. perfringens beta goat 11 at 1:10,000, 1:20,000 and 1:40,000
dilutions respectfully. Lane 10 peroxidase conjugate control for lane 3, goat anti-mouse
at 1:4,000 dilution. Lane 11 peroxidase conjugate control for lane 4 – 9, donkey anti-goat
at 1:4,000 dilution.
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Table 2: Polyclonal antibody 31 weakly neutralizes CPB.
Average End Point
Sample
Dilution (CPE)a
Anti-C. perfringens beta
<2
goat 11
Anti-C. perfringens beta
8
goat 31
Positive Control
256
(Beta toxin Anti-sera)

a

Negative Control
(Alpha toxin Anti-sera)

<2

Average values of two replicates.

Fig. 3: Polyclonal antibody 31 produced a greater signal relative to polyclonal antibody
11 when evaluated by indirect ELISA. Data is representative of the mean OD (OD405 OD490) for each dilution completed in duplicate. The individual polyclonal antibodies
were at an initial concentration of 1:4,000 and diluted 2-fold across the plate.
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2.3.2 MONOCLONAL ANTIBODY SELECTION
Experiments were carried out to determine the most appropriate monoclonal
antibody for use in the ELISA format as the indicator antibody. Forty-one hybridoma
monoclonal antibodies met the selection criteria of having an OD greater than or equal to
0.08 on C. perfringens type C toxoid plates with less than or equal to 0.05 OD on C.
perfringens type A toxoid plates when assessed by MBS. Fulfilling these criteria
demonstrate there was minimal cross reactivity of the 41 monoclonal antibodies for CPA.
The supernatants of hybridoma monoclonal antibodies were further characterized
by western blot analysis to confirm recognition of the 38 kDa beta protein. Of the 41
monoclonal antibodies screened, 11 recognized a 38 kDa protein band (Fig. 4). These 11
monoclonal antibodies were also evaluated using a sandwich ELISA (Fig. 5). Of the 11
monoclonal antibodies, two demonstrated strong reactivity throughout the dilution series.
Importantly, monoclonal antibody 23 gave a strong signal even at the highest dilution,
suggesting a high affinity for the antigen. An ideal monoclonal antibody for an assay has
high affinity for the antigen and neutralizing activity. The neutralizing activity suggests
the antibody recognizes and binds to epitopes on the antigen necessary for protection. To
assess the neutralizing capability of the 11 monoclonal antibodies, neutralizing activity
was evaluated (Table 3). Of the 11 hybridoma monoclonal antibodies, five had
neutralizing activity, including monoclonal antibody 23.
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Fig. 4: Western blot analysis depicting C. perfringens type C beta toxin specific protein
binding by different supernatants of hybridoma monoclonal antibodies. Lane 1 molecular
weight marker. Eight of the 11 individual monoclonal antibodies to detect beta toxin in
lanes 2 through 9 (11, 13, 22, 23, 33, 35, 37, and 40) at a 1:4 dilution. Lane 10 positive
control monoclonal to beta from the CVB at 1:10,000 dilution. Lane 11 peroxidase
conjugate control, goat anti-mouse at 1:4,000 dilution.
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Fig. 5: Hybridoma monoclonal antibodies 23 and 37 produced the greatest signal relative
to the other investigational antibodies when evaluated by sandwich ELISA. Data is
representative of the mean OD (OD405 - OD490) for each dilution completed in duplicate.
The individual monoclonal antibodies were at an initial concentration of 1:2 and diluted
2-fold across the plate.
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Table 3: Capability of hybridoma monoclonal candidates to neutralize CPB.
Average End Point
Monoclonal Number
Dilution (CPE)a
1
<2
11
<2
13
32
18
<2
22
<2
23
128
33
64
35
64
37
128
40
<2
41
<2
CVB 10A2
<2
Fusion Media Control
<2
Positive Control
256
(Beta toxin Anti-sera)
Negative Control
(Alpha toxin Anti-sera)
a
Average values of two replicates.

<2

The five hybridoma candidates which showed to neutralize the beta toxin were
selected and expanded, purified, concentrated and were then reevaluated by western blot
to confirm detection of the 38 kDa protein band (Fig. 6), neutralizing activity (Table 4),
and absence of cross reactivity of alpha toxin by indirect ELISA (Fig. 7). Since alpha
toxin is present in C. perfringens type C cultures, a false positive result could be obtained
if the antibody also reacted to the alpha toxin. To assess the cross reactivity of the five
monoclonal antibodies with neutralizing activity to beta toxin, they were analyzed using
positive and negative indirect ELISA (Fig. 7). The five monoclonal antibodies
demonstrated specificity for C. perfringens type C beta toxoid and did not cross react
with type A toxoid. Taken together, these data demonstrate that monoclonal antibody 23
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has specificity to the beta toxin by western blot, a high affinity as shown by ELISA,
strong neutralizing activity, and no cross reactivity with C. perfringens type A. For these
reasons, monoclonal antibody 23 was chosen for use as the indicator antibody in
developing an in-process ELISA to measure C. perfringens type C toxoid.

Fig. 6: Western blot analysis depicting C. perfringens type C beta toxin specific protein
binding by monoclonal antibody candidates. Lane 1 molecular weight marker. Lane 2
positive control monoclonal to beta from the CVB at 1:20,000 dilution. Lane 3 through 7
monoclonal antibodies 13, 23, 33, 35 and 37 at a 1:10,000 dilution. Lane 8 peroxidase
conjugate control, goat anti-mouse at 1:4,000 dilution.
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Table 4: Monoclonal candidates to neutralize CPB.
Average End Point
Monoclonal Number
Dilution (CPE)a
13
512
23
4096
33
1024
35
2048
37
4096
CVB 10A2
<4
Positive Control
256
(Beta toxin Anti-sera)

a

Negative Control
(Alpha toxin Anti-sera)

<4

Average values of two replicates.

Fig. 7: Monoclonal antibodies 23 and 37 produced the greatest signal relative to positive
control, 10A2, when evaluated by indirect ELISA to C. perfringens type C. All
investigational antibodies were negative when evaluated by indirect ELISA to C.
perfringens type A. Data is representative of mean OD (OD405 - OD490) for each dilution
completed in duplicate. The individual monoclonal antibodies were diluted 2-fold across
the plate with a 1:500 starting dilution.
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2.3.3 IN-PROCESS ELISA DEVELOPMENT AND OPTIMIZATION STEPS
The following are two flow charts outlining the steps used during the
development and optimization of an in-process ELISA.
Development Steps:
Determining capture and indicator anitbody
use dilutions
Establish reference material

Establish positive control material
Outline of developed in-process ELISA
method for optimization
Optimization Steps:
Define assay variables
Determine intra-assay repeatability
Assess within-plate precision or variability
between sample positions on a single plate
Intermediate precision to assess results
obtained between technicians
Assess actual and theoretical values to show
accuracy of the assay
Robustness for assay flexibility
Establishing a positive control range for the
assay
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2.3.4 IN-PROCESS ELISA DEVELOPMENT STEPS
2.3.4.1 CAPTURE AND INDICATOR ANTIBODY USE DILUTION
The appropriate antibody dilutions for use in the in-process ELISA need to be
determined initially to optimize the signal to background ratio. This is important so the
background does not interfere with the signal from the antigen being measured. The
dilutions of the capture antibody (i.e., goat anti-C. perfringens type C 31) and indicator
antibody (i.e., mouse anti-C. perfringens type C clone 23) were determined by
performing a checkerboard assay for evaluating optimal dilutions. Capture antibody
dilutions down the y-axis of a 96-well plate (row A through row H) and the indicator
antibody dilutions were along the x-axis (column 1 through column 12). The plates were
read and the average OD’s were plotted for both capture and indicator antibodies to
determine optimal use dilutions. The optimal use dilution for the capture antibody was
determined to be 1:500, while the indicator antibody optimal use dilution was determined
to be 1:2,000 (Fig. 8 and 9).
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Fig. 8: Optimal dilution for polyclonal antibody 31 was determined to be 1:500 by
checkerboard assay. Black dashed line highlights the 1:500 dilution. The capture
starting dilution was 1:250 in row A and diluted two fold to 1:32,000 in row H.
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Fig. 9: Optimal dilution for monoclonal antibody 23 was determined to be 1: 2,000 by
checkerboard assay. Black dashed line highlights the 1:2,000 dilution. The indicator
starting dilution was 1:250 in column 1 and diluted two fold to 1:512,000 in column 12.

2.3.4.2 FULL CURVE ANALYSIS OF REFERENCE
Reference material must be representative of the samples that will be analyzed in
the ELISA. Since in-process samples are cultures of C. perfringens type C, a
representative lot was chosen as the reference. The reference material is used to generate
a standard curve for determining fermentation yields. To establish the linear range of the
reference, a full curve analysis containing both the upper asymptote and lower asymptote
was performed. For this purpose, C. perfringens type C toxoid bulk antigen lot 166263
was selected as the reference material. Full curve was achieved by starting the bulk
material at a 1:2 dilution (diluted in 1% casein sodium in PBST) on the plate and serially
diluted three-fold from columns 1 through 12 and ran in triplicate (Fig. 10).
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Fig. 10: The linear portion of the reference material was established by full curve analysis
using dilution 1:54 through 1:4,374 (boxed area). Data is representative of mean OD
(OD405 - OD490) for each dilution completed in triplicate. The starting dilution of
reference was 1:2 with three fold dilutions across the plate.
The reference was given an arbitrary stock concentration of 8,040 relative units
per mL (RU/mL), which was based off the L+ value of the bulk antigen. The first point
of the linear region was a 1:54 dilution; this established the starting dilution of the
reference for the in-process ELISA. With a reference stock concentration of 8,040
RU/mL, the starting dilution of the reference at 1:54 would be 148.89 RU/mL. After a
reference has been determined and assigned a stock concentration value, the next step
was to establish a positive control to be used in the ELISA. The positive control ensures
that the reagents have not changed or degraded from assay to assay.
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2.3.4.3 SELECTING A POSITIVE CONTROL
A positive control for an ELISA assay establishes the repeatability of the assay
and stability of the reagents. The positive control should be representative of the samples
that will be analyzed in the assay and similar to the reference material, but from a
different lot. C. perfringens type C toxoid bulk antigen lot 183502 was selected as the
positive control. The positive control and the reference must be linear to each other as
determined by calculating the slope ratio. The slope ratio is calculated by dividing the
slope of the positive control by the slope of the reference (Fig. 11). Linearity is usually
established with slope ratios within 0.8 – 1.25.

Fig. 11: The linear equations for the reference and positive control contained similar
slopes, yielding a slope ratio of 1.01. Starting dilutions of reference (Ref.) and positive
control (PC) was 1:54.
The slope for the positive control was -0.0982 and -0.0971 for the reference
resulting in a slope ratio of 1.01, which was within the acceptable range. After the use
dilutions of the capture and indicator antibodies, and the reference and positive control

42
have been established, the next step is putting them into an appropriate assay format for
assay optimization.

2.3.4.4 IN-PROCESS ELISA FOR OPTIMIZATION
The following briefly describes the method used to optimize the in-process
ELISA (as described in section 2.2.10). The polyclonal capture antibody was dispensed
onto a polystyrene 96-well plate and incubated overnight at 4°C. The next day, the plate
was blocked and incubated. During incubation the reference, positive control and test
articles were prepared for diluting onto a dilution plate. The samples from the dilution
plate were transferred to respective wells of the blocked plate and incubated. The
indicator antibody was added to the plate and then incubated. Next, the peroxidase
conjugate antibody was added to the plate and incubated. ABTS peroxidase substrate
was added to all wells on the plate. The plate was read at 405 nm minus 490 nm
targeting a ≥ 0.8 OD for the first dilution of the reference. This targeted OD is used
during the in-process ELISA optimization; during optimization steps an OD read range is
established.

2.3.5 IN-PROCESS ASSAY OPTIMIZATION STEPS
2.3.5.1 MEAN, STANDARD DEVIATION AND COEFFICIENT OF VARIATION
To evaluate the in-process ELISA, three parameters are determined: the mean and
standard deviation (STD) of replicate samples that are used to calculate the percent
coefficient of variation (%CV). The %CV is calculated by taking the standard deviation
divided by the mean and multiplying by 100. Low %CV indicates less variation between
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replicates and higher precision of the assay. A ≤15% CV would indicate the assay
reagents are performing with acceptable consistency between replicates and in
accordance with Veterinary Services Memoranda 800.112 (United States Department of
Agriculture, 2017b). Variability can arise from any step of the assay and these can be
defined by five different methods for optimizing an assay as described below.

2.3.5.2 INTRA-ASSAY PRECISION OR REPEATABILITY
One optimization parameter is to show the in-process ELISA intra-assay
precision, which is a measure of how repeatable the assay is from plate to plate. To
assess precision and repeatability, one bulk lot was used in one sample position on the
assay plate (i.e., T01, Fig. 1) on six different plates to achieve six replicates. The RU/mL
is calculated by individually applying a linear regression model to the reference, positive
control and test samples. If the slope ratio for the reference and positive control criteria
are met, then the relative potency of the sample is calculated based on the difference in
intercepts and common slopes of the reference and sample. The linear regression model
then calculates a RU/mL. In order to estimate the repeatability, the %CV of the RU/mL
was calculated to determine if the six replicates demonstrated a %CV ≤ 15%.
Table 5: Intra-assay precision of the in-process ELISA.
Antigen Lot
Plate #
RU/mL
1
6230
2
6307
3
7023
169196
4
6163
5
6447
6
6365
Mean RU/mL
6423
STD
311
5
%CV
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Intra-assay precision of the assay method was evaluated with bulk lot 169196 and
the RU/mL results were calculated by measuring the bulk lot against the known reference
(Table 5). The %CV of the six replicates was 5%, meeting the criteria for intra-assay
precision.

2.3.5.3 WITHIN-PLATE PRECISION
The next step in assay optimization is to assess within-plate precision, which
evaluates the variability between sample positions on a single plate using the same
sample bulk. A similar RU/mL result should be achieved regardless of which sample
position (T01, T02 or T03) the test article is placed on the plate. The RU/mL data from
all three samples positions on two plates were analyzed in order to estimate and calculate
the %CV for the within plate precision (Table 6).
Table 6: Within-plate precision of the in-process ELISA.
Plate 1
Plate 2
Antigen
Lot
Position
RU/mL
T01
12252
12289
183502
T02
12210
11891
T03
12699
12277
12387
12152
Mean RU/mL
271
226
STD
2
2
%CV
Within-plate precision of the assay method was evaluated with bulk lot 183502 by
testing all three sample positions on two separate plates. Testing was completed on one
day and the RU/mL was calculated by measuring the bulk lot 183592 against the known
reference. The %CV’s were less than 5% for the two plates, meeting the validation
criteria for within-plate precision ≤ 15%.
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2.3.5.4 INTERMEDIATE PRECISION
Another optimization step for the in-process assay is to show different personnel
can achieve the same results with the same sample. Intermediate precision is established
by comparing assay results obtained from different technicians within the same
laboratory. The intermediate precision was assessed by evaluating one bulk lot at 100%
and diluted to two different concentrations. Two different analysts each performed two
replicate plates. Precision was evaluated by calculating the %CV for each preparation
(Table 7).
Table 7: Intermediate precision of the in-process ELISA.

Antigen Lot

Replicate

169196

1
2

Technician
1
2
1
2
Mean RU/mL
STD
%CV

T01
(100%)
6697
5863
6420
7074
6514
510
8

Sample
T02
(70%)
RU/mL
4289
3731
4448
4495
4241
352
8

T03
(30%)
1888
1692
2035
1811
1857
144
8

Intermediate assay precision evaluated one bulk lot at three different
concentrations which were 100%, 70% and 30%. Intermediate CV’s for RU/mL was
calculated by measuring the bulk lot 169196 against the known reference. The %CV’s
were 8%, meeting the validation criteria for intermediate precision of ≤ 15%.

2.3.5.5 ACCURACY
After establishing intermediate precision, the next step for the in-process assay is
to assess the accuracy of the assay. Accuracy is the closeness of the assay value to the
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predicted value based on analysis of the sample to the reference. For example, a bulk lot
can be measured relative to a standard curve to obtain a value for that bulk lot. The same
sample can then be diluted and the value should be known. For instance, the accuracy of
the assay was determined by comparing the measured RU/mL to the theoretical RU/mL
of three bulk lot preparations. The measured RU/mL of the non-diluted, 100%, bulk lot
(T01) and its two diluted preparations, 70% and 30% (T02 and T03) were compared to
their theoretical RU/mL. The calculated difference (percent of theoretical) in RU/mL
between measured and theoretical values were compared (Table 8). The difference
(percent of theoretical) in RU/mL between the measured and theoretical values for T02
and T03 were calculated as follows;
Percent of theoretical RU/mL = 100 * (measured RU/mL ÷ theoretical RU/mL)
Table 8: Comparison of measured RU/mL to theoretical RU/mL values demonstrating
accuracy of the in-process ELISA.
Antigen Lot

169196
T01

Rep
1
2

T02

173883
T03

T01

Tech

T02

182291
T03

T01

T02

T03

RU/mL

1

6697

4289

1888

8426

5687

2490

7976

4862

2234

2

5863

3731

1692

8707

6035

2514

9181

6122

2843

1

6420

4448

2035

7792

5358

2256

7758

5576

2195

2

7074

4495

1811

6649

5120

1905

9024

6151

2128

6514

4241

1857

7894

5550

2291

8485

5678

2350

4560

1954

5525

2368

5939

2545

93

95

100

97

96

92

Mean RU/mL
Theoretical
RU/mL
% Theoretical

The acceptance criterion for the accuracy of an assay has been internally
established to fall within the range of 85 – 115 % theoretical. The theoretical RU/mL is
calculated by multiplying the non-diluted sample (T01) mean RU/mL result by 70% or
30% for samples T02 and T03 respectively (Table 8). Samples T02 and T03 for each of
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the three bulk lots show the measured RU/mL relative to the calculated theoretical
RU/mL and resulted in % theoretical values within the acceptable range.

2.3.5.6 ROBUSTNESS
Determining robustness of an assay gives the operator a defined range of OD to
yield confidence in the assay output. Robustness of the assay with regard to plate reading
range was evaluated by one analyst assaying one plate per day and repeating this over
three days. Each plate was read at a range of 0.6 – 1.1 OD for the reference lot 166263
and the RU/mL data is analyzed by comparing %CV (Table 9).
The minimum and maximum read range was evaluated by one analyst. The
positive control (lot 183502) was used as the sample bulk measured for T01, T02 and
T03. On each of the three assay days, a single plate was read at an early (0.6) through
late (1.1) OD. The data shows that a reading range of the first reference dilution points,
1:54 dilution (wells B2 and B7 in Figure 1), from 0.6 – 1.1 OD is an acceptable range for
potency assay robustness, generating an overall average %CV of 3% across the three
assay days.
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Table 9: Variation between the minimum and maximum read range values.
PC
T01
T02
T03
Mean
Average
a
Day
OD
RU/mL
RU/mL
%CV
0.6
11608 11903
11311
11502
11572
0.7
11622 11795
11478
11498
11590
0.8
11751 11877
11879
11577
11778
1
2
0.9
11825 11890
11733
11902
11842
1.0
12135 12223
12054
11648
11975
1.1
12190 12594
12447
11931
12324
0.6
12720 12165
11448
13069
12227
0.7
12637 12477
11444
12714
12212
0.8
12896 12252
12210
12699
12387
2
3
0.9
13133 12580
11788
13278
12549
1.0
13179 12830
12011
13429
12757
1.1
13959 12872
13100
13121
13031
0.6
10689
9966
10107
10859
10311
0.7
10508 10111
10183
10461
10252
0.8
10575 11135
10350
10838
10774
3
5
0.9
10736 11324
10993
11050
11122
1.0
11626 11487
11235
11497
11406
1.1
11713 11599
11164
11221
11328
a

Average OD reading of reference first dilution points in wells B2 and B7.

2.3.5.7 ESTABLISHING POSITIVE CONTROL RANGE
After the other assay parameters had been optimized, the last step was to establish
a positive control range. The positive control range is another measurement used to
ensure day to day and operator to operator consistency. The assay is satisfactory when
the positive control is within the range for each assay plate assessed. Establishing the
positive control range was achieved by three different technicians running six plates on
three separate days. The standard deviation of the mean was determined and the range
was established by plus and minus two times the standard deviation of the mean. The
mean RU/mL from each of the three technicians and the positive control range was
established to be 9,556 – 13,838 RU/mL (Table 10).
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Table 10: Positive control range for the in-process ELISA was established using
mean variation between three individual runs.
Day/Tech
PC lot 183502
Plate #
(RU/mL)
Day 1 Tech 1
1
11277
2
11161
3
11051
4
11168
5
10532
6
11956
Day 2 Tech 2
7
11599
8
12297
9
10087
10
11749
11
11908
12
11631
Day 3 Tech 3
13
11699
14
11550
15
12311
16
11096
17
15284
18
12199
Mean RU/mL
11698
Standard Deviation (STD)
1070
%CV
9
Positive Control Range
9,556 – 13,838
Ru/mLa
a

Values determined by ± two times the standard deviation of the mean.

2.3.6 EVALUATION OF ELISA COMPARED TO L+ ASSAY
Eleven bulk antigens of C. perfringens type C toxoid with known L+ values were
measured using the optimized in-process ELISA. These results were plotted to determine
the correlation between the two different assays (Fig. 12). This analysis was done to
determine if the in vitro ELISA could directly replace the mouse L+ assay as the in-
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process assay. The cumulative R2 value was 0.4048 indicating low correlation of L+
values to measured RU/mL values.

Fig. 12: L+ values compared to measured RU/mL values of eleven bulk antigen lots
showed low correlation between L+ assay and in-process ELISA; R2 value of 0.4048
(trend line).

2.4 DISCUSSION
Clostridial species importance is due in part to the fact that they can be found in
many environments including soil, water and mammals. While they frequently exist as
commensals, C. perfringens can be the cause of severe disease in both humans and
animals. Outbreaks of C. perfringens causing necrotic enteritis in neonates can have a
great economic impact on livestock producers. Effective vaccines have been developed
to help prevent outbreaks, but they can be expensive due to the test methods involved in
the production and release of the vaccines. Currently, the beta toxoid form is a common
immunogen used in C. perfringens type C vaccines. To determine the potency of
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production runs and facilitate blending of vaccines products, the potency test methods
involve the use of lethal mouse assays. An in vitro method for testing the beta toxoid of
C. perfringens would reduce the expense of vaccine production by eliminating or
reducing the use of laboratory animals. The data presented in this thesis details the
development of a robust and precise in-process ELISA method (below the industry
standard of 15% CV) for detecting and quantifying beta toxoid in cultures of C.
perfringens type C.
In this study, a monoclonal antibody specific to the beta toxoid from C.
perfringens type C was generated and selected for developing an in vitro in-process
ELISA assessing beta toxoid yield. This monoclonal antibody had high specificity to the
beta toxin via western blot, produced a high ELISA signal to the beta toxoid and strong
neutralizing activity with no cross reactivity to C. perfringens type A alpha toxoid. This
monoclonal antibody, and a selected polyclonal antibody, allowed for the development of
an in-process ELISA that is specific to the beta toxoid.
The development of in vitro Clostridium toxoid assays has produced a diverse
collection of protocols with varying utility. Redhead, K., et al. described a C. septicum
in-process assay using Vero cells, which are sensitive to the toxin from C. septicum, and
showed a correlation between their cell-based assay and mouse L+ test assay results.
They concluded the mouse L+ test could be replaced by their cell-based assay (Redhead
et al., 2011). While the cell-based assay was more accurate than the mouse L+ test and
eliminated the use of mice, this method measures toxin but cannot quantify toxoid in
production fermentation batches. In addition to cell line-based assays, ELISA methods
(i.e., sandwich, blocking, and competitive assays) have been used to develop serological
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assays for measuring the presence of anti-C. perfringens beta toxin in rabbits, pigs, cattle,
sheep and horse serum. ELISA methods have the potential to reduce the use of mice for
assessing the presence of serum antibodies in the final potency test, but does not
eliminate animal usage altogether (Krt, 1999). Another ELISA method tried to replace
the mouse neutralization test for estimating levels of beta toxin antitoxin in the sera of
immunized rabbits for final potency testing. This in vitro method uses an ELISA where a
monoclonal antibody to beta toxin is coated on the plate to capture C. perfringens beta
toxin, which then binds beta antitoxin in rabbit sera (Ebert et al., 1999). While this
method had a good correlation between in vivo and in vitro for testing sera potencies,
rabbits are still vaccinated first in order to obtain final potency results. To date, the
available assays were not designed for quantifying antigen for vaccine input. The
sandwich ELISA described in this thesis is an alternative to the current L+ test that will
potentially reduce the use of experimental animals. An ELISA would be a high through
put advantage able to test greater number of samples in a shorter period of time, more
economical and have better consistency of batch to batch vaccine assembly in
comparison to assembling vaccines based on in vivo testing. This ELISA would also
have the potential to replace the current potency testing of C. perfringens type C vaccines
as described in 113.111 of the USDA 9CFR and in monograph 363 of the EP.
The research described here has shown the development of an optimized ELISA
method for detecting and quantifying C. perfringens type C beta toxoid. However, the in
vivo L+ values were shown not to correlate with the ELISA RU/mL values. Figure 12
illustrated there was low correlation between the L+ values and the average measured
RU/mL values. Values generated by the L+ assay are not directly indicative of the
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quantity of beta toxin present in the C. perfringens type C material, which could be why
variability is seen in animal testing. The L+ is measuring the antigenicity of toxin verses
the toxoid being quantified with a specific antibody in the in-process ELISA.
In order to replace the L+ test with the developed ELISA, additional experiments
would need to be completed. Using the developed ELISA, one approach would be to
perform the in-process ELISA method on formulated vaccines. If the in-process ELISA
could also detect beta toxoid in final vaccine, then this would aide in quantitatively
determining the protective dose in current vaccines. Another approach would be to
obtain toxoid antigen with known L+ value and measure the toxoid material in the inprocess assay to determine the respective RU/mL value of the bulk. Vaccines could be
prepared with toxoid antigen at different RU/mL levels for vaccinating mice and the mice
would be challenged with a known amount of beta toxin that is lethal in mice. By
repeating this with multiple antigen bulks of type C toxoid, one could define the potential
protective dose in mice. After mouse challenge studies had been completed, large animal
studies, species specific, would need to be conducted showing the protective minimum
immunizing dose (MID). This is now possible due to the generation of reagents which
are the monoclonal and polyclonal antibodies to beta toxoid material as well as the
method for use of those reagents.
In my research, I assessed and selected a polyclonal and a monoclonal antibody
and optimized the concentrations used to detect the C. perfringens type C toxoid. These
antibodies had specificity to beta toxin and toxoid and exhibited neutralizing activity;
hence, can to be used as the capture and indicator for developing an in-process ELISA.
The USDA requires the reagents in these types of in vitro methods correlate to protection
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either by specificity to protective epitopes or by the ability to neutralize antigens that
cause disease. Through a combination of western blots, neutralization assay and
ELISA’s, I identified which antibodies would be appropriate for the assay. This
optimized in-process ELISA could potentially replace the mouse L+ test which would
reduce the use of animals to measure the type C toxoid material and potentially improve
C. perfringens type C vaccine production through batch to batch consistency, decreased
testing time and could improve cost of the product.
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